TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04516876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camp-based bimanual intensive training(BIT)
Description: The day-camp BIT model will be delivered in a group-based design. In day-camp model, each child is assigned to a trained therapist to maintain at least a 1:1 to 1:2 ratios of therapy and child. The therapist will monitor and modify the activities to fit each individual's ability and need to make sure the intervention quality is equivalence to the individualized treatment method. The chosen tasks of each intervention session have to be considering the child's preference, age-appropriated, and at the right level of difficulty. Target movements are embedded in the functional activities, whereby the environment is manipulated to vary task requirement and the difficulty is graded to match the child's capacity.
Study: NCT03626675

Intervention type: PROCEDURE
Group type: OTHER
Intervention: phaco- trabeculectomy
Description: combined phaco-trabeculectomy surgery
Study: NCT01067300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation of unrelated cord blood unit(s)
Description: Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation of unrelated cord blood unit(s)
Description: Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
Study: NCT04607031

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke
Description: 7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications
Study: NCT00080106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRK Ad5 HIV-1 gag vaccine
Description: MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine placebo
Description: MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
Study: NCT03846375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: DBT is a well-established treatment for recurrent self-harm and suicidal thoughts. The program is principle-based, but the skills training follow a manualized curriculum.

Intervention type: OTHER
Group type: OTHER
Intervention: Pre-intervention testing
Description: Pre-intervention testing for baseline measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-intervention testing
Description: Pre-intervention testing for baseline measures.
Study: NCT02701491

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: ginger

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02512562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-335
Description: AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-335
Description: AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACH-3102
Description: ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACH-3102
Description: ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simeprevir
Description: Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simeprevir
Description: Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
Study: NCT01249196

Intervention type: DRUG
Group type: OTHER
Intervention: SK-PC-B70M
Description: for dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SK-PC-B70M
Description: for dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-PC-B70M
Description: for dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-PC-B70M
Description: for dosage
Study: NCT02679105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard birch or 5-grasses
Description: 3 injections with 4-5 weeks interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK diluent
Description: 0,3% human albumin
Study: NCT03868371

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High phosphorous containing meal
Description: A meal with a high phosphorous content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High phosphorous containing meal
Description: A meal with a high phosphorous content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low phosphorous containing meal
Description: A meal with a low phosphorous content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low phosphorous containing meal
Description: A meal with a low phosphorous content
Study: NCT03514797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleaching Agents
Description: In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleaching Agents
Description: At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleaching Agents
Description: At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
Study: NCT01560702

Intervention type: DRUG
Group type: OTHER
Intervention: Epinephrine
Description: 10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood
Description: 5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
Study: NCT03120793

Intervention type: DEVICE
Intervention: Esophageal balloon catheter
Description: Measurements obtained from mechanically ventilated patients with ARDS in the supine, upright and prone positions
Study: NCT04249778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
Study: NCT03233217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-HD by IM
Description: IM, injected into the upper arm (deltoid area)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-HD by IM
Description: IM, injected into the upper arm (deltoid area)
Study: NCT04571632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab 100 MG in 4 ML Injection
Description: The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab 100 MG in 4 ML Injection
Description: The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC
Description: CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions \< 0,5 cm to 4.0 mL for lesions \> 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC
Description: CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions \< 0,5 cm to 4.0 mL for lesions \> 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size.
Study: NCT03233217

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV-SD by SC
Description: SC, injected into the upper arm (posterior region)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-HD by SC
Description: SC, injection into the upper arm (posterior region)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-HD by SC
Description: SC, injection into the upper arm (posterior region)
Study: NCT01590875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine arm
Description: In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
Study: NCT00886457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Pegylated Interferon-Alfa 2B
Description: Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
Study: NCT03602781

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at a dose setting of 75 mcg/kg IBW/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iNO
Description: iNO at a dose setting of 75 mcg/kg IBW/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iNO
Description: iNO at a dose setting of 75 mcg/kg IBW/hr
Study: NCT03535415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone Injection (rhGH)
Description: rhGH 0.05mg/kg/d by subcutaneous injection
Study: NCT04113993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene Acetate
Description: Oral Bazedoxifene dosed at 40 mg daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically packaged placebo capsule daily
Study: NCT02015156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280014
Description: Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
Study: NCT01197066

Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol 200mg
Study: NCT02013427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Take one 500mg naproxen capsule twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one placebo capsule twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Take one 20mg omeprazole capsule twice a day.
Study: NCT03100747

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilamellar 3 mm
Description: Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3 mm from the eyelid margin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilamellar 5 mm
Description: Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5 mm from the eyelid margin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabut 3 mm
Description: Trichiasis surgery using Trabut procedure with incision 3 mm from the eyelid margin
Study: NCT03906994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video game Mario Kart Wii
Description: Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior
Study: NCT00165698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: menatetranone
Description: 15 mg three times a day orally for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfacalcidol
Description: 0.25 μg twice a day orally for 12 months
Study: NCT04393948

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 1
Description: Dose Level 1 - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 1
Description: Dose Level 2 - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 2
Description: Arm A - No irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 2
Description: Arm B - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 2
Description: Arm C - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
Study: NCT02177357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03770455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2nd generation ADT (abiraterone or enzalutamide)
Description: 2nd generation ADT (abiraterone or enzalutamide)
Study: NCT01143012

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group eczema education session
Description: Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will not attend the group eczema education session.
Study: NCT02602327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tas-102
Description: Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Sphere
Description: 20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
Study: NCT03676829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial Embolization of the Shoulder
Description: Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
Study: NCT03137004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50mg/m2 in 60 min on day 1 and repeated every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 was administered orally at 40 mg/m2 twice daily on days 1-7 of each cycle. Patients with a body surface area of less than 1.25 m2 received 80 mg S-1 daily, those with a body surface area of 1.25 m2 or more but less than 1.5 m2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m2 or more received 120 mg S-1 daily.
Study: NCT02929004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrasens
Description: Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
Study: NCT02546570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: See arm/group descriptions for dosage amount and procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: See arm/group descriptions for dosage amount and procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: See arm/group descriptions for dosage amount and procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See arm/group descriptions for dosage amount and procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See arm/group descriptions for dosage amount and procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See arm/group descriptions for dosage amount and procedure.
Study: NCT03630900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential O2 Culture
Description: We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
Study: NCT02863042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair Deltoid Tendon

Intervention type: OTHER
Group type: OTHER
Intervention: Ankle Fracture Without Deltoid Tendon Repair
Description: Standard of care
Study: NCT04168086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The investigators will simulate focused ultrasound stimulation similar to the experimental groups but without stimulation.
Study: NCT00787293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant
Description: Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
Study: NCT00873002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: panobinostat
Description: Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib tosylate
Description: 400 mg PO BID
Study: NCT02594501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBRA PzF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Stent
Study: NCT01424852

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics in infant milk formula
Description: Probiotic infgant milk formula administered during the forst year of life

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics in infant milk formula
Description: Probiotic infgant milk formula administered during the forst year of life
Study: NCT02899871

Intervention type: OTHER
Intervention: diagnosis of joint
Description: The diagnosis of joint pain will be established by a rheumatologist and completed:~* If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~* serum assays of the anti-TNF administered, as well as screening for associated antibodies.

Intervention type: OTHER
Intervention: diagnosis of joint
Description: The diagnosis of joint pain will be established by a rheumatologist and completed:~* If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~* serum assays of the anti-TNF administered, as well as screening for associated antibodies.